Pipeline

Overview

HomePipelineOverview

ABL001

  • Pipeline
    ABL001
  • Program Target
    VEGF x DLL4
  • Disease Indication
    Solid Tumor
  • Development Stage
    Clinical Development
    (Phase 1a/1b)
Summary
Better anti-cancer efficacy of ABL001 at in vitro/in vivo studies are confirmed with cancer patients in clinical trial (phase 1a/1b).
ABL001 can be developed as the next generation of anti-angiogenic therapy.

MOA of ABL001

Dual blockade of VEGF & DLL4 overcomes VEGF resistance

MOA of ABL001
MOA of ABL001

POC of ABL001 in Preclinical Study

Better efficacy compared to Avastin or anti-DLL4 monotherapy

POC of ABL001 in Preclinical Study
POC of ABL001 in Preclinical Study

Clinical Response of ABL001

3 Patients showed confirmed partial response (PR) in phase 1a/1b study

Clinical Response of ABL001
좌우스크롤 Clinical Response of ABL001

닫기

ABL105

  • Pipeline
    ABL105
  • Program Target
    HER2x4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Late-Stage Research
Summary
ABL105 is a bispecific antibody that targets HER2 and 4-1BB simultaneously. ABL105 crosslinks and activates 4-1BB signaling only in the presence of tumor cells in a HER2 expression-dependent manner, while lacking 4-1BB clustering and T cell activation in normal tissues. In addition, ABL105 blocks HER2 signaling and induces NK cell-mediated cytotoxicity, thereby showing stronger anti-tumor activity. ABL105 significantly inhibits tumor growth and protects mice from tumor re-challenge by inducing tumor specific memory.

MOA of ABL105

ABL105 in the Grabody™-T BsAb Platform activates T-cells only in the Tumor Microenvironment

MOA of ABL105
MOA of ABL105

Tumor Specific 4-1BB Activation

ABL105 activates 4-1BB signaling only in the presence of tumor cells in a HER2 expression-dependent manner

Tumor Specific 4-1BB Activation
Tumor Specific 4-1BB Activation

Strong Anti-Tumor Effect

ABL105 inhibits tumor growth and protects mice from tumor re-challenge by inducing tumor specific memory

Strong Anti-Tumor Effect
좌우스크롤 Strong Anti-Tumor Effect

닫기

ABL111

  • Pipeline
    ABL111
  • Program Target
    Claudin18.2x4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Early Development
Summary
ABL111 is a bispecific antibody combining Claudin18.2, a gastric- and pancreatic-specific cancer antigen with 4-1BB agonistic activity to supercharge T cells in a Claudin18.2-dependent manner, enhancing anti-tumor immunity while minimizing 4-1BB related toxicity. ABL111 is full length anti-Claudin18.2 mAb (Fc-silenced human IgG1) fused with scFv of anti-4-1BB engaging mAb. ABL111 possesses unique properties that 4-1BB activation signal is dependent on Claudin18.2 expression. ABL111 shows superior anti-tumor activity in an animal model system than Claudin18.2 alone, 4-1BB alone or combination of both with immunological memory resistant to rechallenge with same tumors.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

Claudin18.2 Dependent 4-1BB Activation

Claudin18.2 Dependent 4-1BB Activation
Claudin18.2 Dependent 4-1BB Activation

Superior Anti-Tumor Effect with Immunological Memory

Superior Anti-Tumor Effect with Immunological Memory
좌우스크롤 Superior Anti-Tumor Effect with Immunological Memory

닫기

ABL301

  • Pipeline
    ABL301
  • Program Target
    SNCA x IGF1R
  • Disease Indication
    Parkinson’s Disease
  • Development Stage
    Late-Stage Research
Summary
Propagation of aggregated form of alpha synuclein (α-syn) appears to be critical for etiology of Parkinson’s disease and multiple system atrophy. ABL301 specifically targets aggregated forms of α-syn, potential disease target, Devoid of its normal, monomeric form.
Since poor delivery of antibody into the brain is thought to be one of the major obstacles for CNS-related drug development, ABL301 has a shuttle antibody to allow improved delivery of antibody therapeutics into the brain.
These dual mechanisms will provide more efficient reach of antibody therapeutics to its target, leading to better therapeutic Efficacy than conventional monoclonal antibody.
Figure from biopharmadeal makers (2017)
좌우스크롤 Figure from biopharmadeal makers (2017)

닫기

ABL501

  • Pipeline
    ABL501
  • Program Target
    PD-L1 x LAG-3
  • Disease Indication
    Solid Tumor
  • Development Stage
    Early Development
Summary
ABL501 is a bispecific antibody combining PD-L1 and LAG-3 checkpoint pathways to overcome the current limitation of PD-(L)1 therapy by blocking two immune suppressors. ABL501 is a full length anti-LAG-3 mAb fused with scFv of PD-L1 engaging mAb. ABL501 shows better activity over combination or bispecific antibody of anti-PD-1 and anti-LAG-3 from competitors. ABL501 shows superior activity than monotherapy and combination.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

Superior Activity than Mono and Combination

Superior Activity than Mono and Combination
Superior Activity than Mono and Combination

Superior Activity over Competitors

Superior Activity over Competitors
Superior Activity over Competitors

닫기

ABL503

  • Pipeline
    ABL503
  • Program Target
    PD-L1 x 4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Early Development
Summary
ABL503 is a bispecific antibody combining PD-L1 checkpoint pathway with 4-1BB agonistic activity to overcome the current limitation of PD-(L)1 therapy and 4-1BB related toxicity. ABL503 is full length anti-PD-L1 mAb (Fc-silenced human IgG1) fused with scFv of anti-4-1BB engaging mAb. ABL503 possesses unique properties that 4-1BB activation signal is only induced in the presence of PD-L1 expressing tumors. ABL503 shows superior anti-tumor activity in an animal model system than PD-L1 alone, 4-1BB alone or combination of both with immunological memory resistant to rechallenge with same tumors.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

PD-L1 Dependent 4-1BB Activation

PD-L1 Dependent 4-1BB Activation
PD-L1 Dependent 4-1BB Activation

Superior Anti-Tumor Effect with Immunological Memory

Superior Anti-Tumor Effect with Immunological Memory
Superior Anti-Tumor Effect with Immunological Memory

닫기

ABL202

  • Pipeline
    ABL202
  • Program Target
    ROR1
  • Disease Indication
    CLL/TNBC
  • Development Stage
    Early development
Summary
ABL202 is an ADC comprised of a ROR1-specific antibody and a highly potent cytotoxic payload, and can deliver the payload to ROR1-expressing cells. ROR1 is a membrane protein whose expression is specifically elevated in cancers including chronic lymphocytic leukemia, breast cancer, and lung cancer. It is suspected that ROR1 is involved in tumor metastasis. ABL202 acts on ROR1 expressing cells and kill the target expression cells.
ABL202
좌우스크롤 ABL202

닫기